Devyser and Thermo Fisher Scientific expand the collaboration for post-transplant NGS products by adding Brazil

Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including Brazil in the exclusive collaboration and distribution agreement for Devyser’s post-transplant portfolio of NGS products. In addition to North America and Europe, Thermo Fisher will now exclusively market and sell Devyser’s transplantation products under combined brands also in Brazil.  

 

“We are very excited to enter into this agreement. Up to now, our products have not been available in the large Brazilian market, and we are highly optimistic about future sales in the country, which has the second-highest number of transplanted organs globally. The agreement provides laboratories in Brazil access to genetic tests that are simple, fast, and easy to use. We are convinced that Thermo Fisher, the leading innovator in the HLA industry, will do this very successfully”, says Fredrik Alpsten, CEO at Devyser. 

 

In Brazil, a total of approximately 6,000 kidneys are transplanted every year. Only the US has a higher number of transplantations. The agreement includes One Lambda Devyser Chimerism for early detection of graft rejection in stem cell transplanted patients and One Lambda Devyser Accept cfDNA, a novel test for detecting donor-derived cell-free DNA in blood samples from kidney transplant patients.  

 

The information was submitted for publication, through the agency of the contact persons below, on September 6, 2023 at 08.00 CET. 

 

For more information, please contact: 

Fredrik Alpsten, CEO 

Email: [email protected] 

Telephone: +46 70 667 31 06  

 

Sabina Berlin, CFO  

Email: [email protected] 

Telephone: +46 73 951 95 06 

 

About Devyser  

Devyser develops, manufactures, and sells diagnostic solutions and analysis services to clinical laboratories in more than 50 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of many genetic diseases, and transplant patient follow-up. Devyser’s products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time, and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. 

Devyser was founded in 2004 and is based in Stockholm, Sweden. The company has eight in-house sales offices in Europe and the US, and a CLIA certified laboratory in Atlanta, Georgia. In August 2022, Devyser's quality management system was certified according to the IVDR. 

Devyser’s shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company’s Certified Adviser is Redeye AB.  

For more information, visit www.devyser.com.